TG Therapeutics, Inc. (TGTX) News
Filter TGTX News Items
TGTX News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
TGTX News Highlights
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
Latest TGTX News From Around the Web
Below are the latest news stories about TG THERAPEUTICS INC that investors may wish to consider to help them evaluate TGTX as an investment opportunity.
Should You Invest in TG Therapeutics (TGTX)?ClearBridge Investments, an investment management company, released its “ClearBridge Small Cap Growth Strategy” fourth quarter 2024 investor letter. A copy of the letter can be downloaded here. A partial change in leadership in the second half of 2024 may continue into 2025 as a number of macro factors stabilize and small-cap earnings growth is expected […] |
TG Therapeutics to Participate in the 43rd Annual J.P. Morgan Healthcare ConferencePresentation scheduled for Monday, January 13, 2025, at 4:30 PM PTNEW YORK, Jan. 09, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that Michael S. Weiss, the Company’s Chairman and Chief Executive Officer, will present at the 43rd Annual J.P. Morgan Healthcare Conference. The presentation is scheduled to take place on Monday, January 13, 2025, at 4:30 PM PT. A live webcast of this presentation will be available on the Events page, located within the Investors & M |
TG Therapeutics price target raised to $10 from $9 at BofABofA raised the firm’s price target on TG Therapeutics (TGTX) to $10 from $9 and keeps an Underperform rating on the shares. While political and rate uncertainty continues to be an overhang, the firm views the health of the Biopharma sector as “markedly improved from 2022 lows.” For stocks in its coverage, the firm continues to like late-stage clinical or early launch stories, although it sees Phase 1 clinical programs with derisking data and near-term catalysts as “increasingly areas of investo |
Will TG Therapeutics, Inc. (TGTX) Make You Rich In 2025?We recently compiled a list of the 10 Stocks That Will Make You Rich In 2025. In this article, we are going to take a look at where TG Therapeutics, Inc. (NASDAQ:TGTX) stands against the other stocks that will make you rich in 2025. What to Expect from the Stock Market in 2025 Jurrien Timmer, Director […] |
High Growth Tech Stocks To Watch In The United StatesThe market remained flat over the last week but has risen 27% over the past 12 months, with earnings forecast to grow by 15% annually. In this context, identifying high growth tech stocks involves looking for companies that demonstrate strong innovation and adaptability, positioning them well in an evolving economic landscape. |
TG Therapeutics to Participate in the Evercore HealthCONx ConferenceFireside chat scheduled for Tuesday, December 3, 2024, at 10:00 AM ETNEW YORK, Nov. 29, 2024 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced that Michael S. Weiss, the Company’s Chairman and Chief Executive Officer, will participate in the 7th Annual Evercore HealthCONx Conference, being held at the Loews Coral Gables Hotel, in Florida on December 3-5, 2024. The fireside chat is scheduled to take place on Tuesday, December 3, at 10:00 AM ET. A live webcast of the firesid |
TG Therapeutics price target raised to $43 from $30 at JPMorganJPMorgan raised the firm’s price target on TG Therapeutics (TGTX) to $43 from $30 and keeps an Overweight rating on the shares. The firm says that with a potential SC Briumvi formulation coming into view beginning in the first half of 2025, it updated TG’s model to reflect risk adjusted Briumvi forecasts within the at-home/self-administered anti-CD20 segment of relapsing multiple sclerosis. At $3.5B, the analyst’s peak Briumvi SC forecast assumes market entry beginning in 2028 and ultimately gar |
TG Therapeutics Ranked Number One Fastest-Growing Company in North America on the 2024 Deloitte Technology Fast 500™NEW YORK, Nov. 21, 2024 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced it ranked number one on the Deloitte Technology Fast 500™, a ranking of the 500 fastest-growing technology, media, telecommunications, life sciences, fintech, and energy tech companies in North America, now in its 30th year. The Company’s growth between fiscal years 2020 to 2023 was fueled by BRIUMVI® revenues, which was approved to treat adult individuals with relapsing forms of multiple sclerosis |
Exploring 3 High Growth Tech Stocks in the United StatesOver the last 7 days, the United States market has risen by 5.7%, contributing to a remarkable increase of 37% over the past year, with earnings anticipated to grow by 16% annually in the coming years. In this dynamic environment, identifying high growth tech stocks involves looking for companies that demonstrate strong innovation and adaptability to capitalize on these favorable conditions. |
TG Therapeutics, Inc. Just Missed Earnings - But Analysts Have Updated Their ModelsIt's been a good week for TG Therapeutics, Inc. ( NASDAQ:TGTX ) shareholders, because the company has just released its... |